Skip to main content

Advertisement

Table 3 American Diabetes Association (ADA) Classification at Baseline1

From: Reduced viscosity Barley β-Glucan versus placebo: a randomized controlled trial of the effects on insulin sensitivity for individuals at risk for diabetes mellitus

Parameter ADA Classification Placebo (N = 17) 3 g/d BBG (N = 16) 6 g/d BBG (N = 17) p-value2
Fasting Plasma Glucose (mg/dL) Normal: Fasting Plasma Glucose < = 99 mg/dL 9; 95.1 (1.3) 6; 91.7 (2.9) 7; 91.0 (2.5) 0.335
  Impaired: Fasting Plasma Glucose 100- 125 mg/dL 8; 110.3 (2.4) 9; 108.2 (2.1) 10; 105.6 (1.0) 0.218
  Diabetes Mellitus: Fasting Plasma Glucose >= 126 mg/dL   1; 145.0   
OGTT (mg/dL): 2 hrs post dose Normal: Glucose at 2 hours < = 139 mg/dL 9; 94.6 (7.7) 11; 101.3 (8.0) 13; 103.5 (6.8) 0.699
  Impaired: Glucose at 2 hours 140-199 mg/dL 5; 169.6 (8.1) 3; 176.3 (13.9) 3; 160.3 (3.7) 0.568
  Diabetes Mellitus: Glucose at 2 hours >= 200 mg/dL 3; 212.0 (5.0) 2; 229.5 (2.5) 1; 201.0 0.093
  1. Values presented are N; Mean (Standard Error of Mean)
  2. 1 Data represented includes all randomized subjects
  3. 2 P-values generated for each group by ANOVA with treatment group as factor.